No one benefits from suppressing better cancer treatments
TORONTO, ON / ACCESSWIRE / [January 23rd, 2019] / The Wealthy Venture Capitalist (or ”WVC”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech and pharma stocks making news and subsequent market moves, would like to update investors on several new advancements in cancer therapies.
The Internet is full of people who know a little and think they’re experts. Laboratories are full of experts who are sure they only know a little. The clash between those who assume that the biggest brains and the biggest companies are all working together to keep people sick is especially sharp when it comes to the dreaded disease of cancer. What’s the reality of cancer drug development, and why does it seem that we are crawling along without cures even as other diseases can be eradicated with mass-produced, affordable vaccines?
Not conspiracy, just difficulty
Talk to a cancer researcher or read a biography of one and you’ll likely encounter a story of personal tragedy, where loved ones or they themselves were attacked by rogue cells in their own body. They work to honor the fallen and protect their children. They learn, they dig deep, and they publish their discoveries. Cancer spreads not only as a disease but in its effects on the community, and that is why it draws such heavy attention and funding. Researchers, providers, and patients are all hungry for new treatments that will prevent harm and cost. The cost side is near and dear to insurance companies and national health systems that are seeing mounting public costs associated with cancer.
The rise in environmental carcinogens in recent generations in the industrial age means that food we eat, materials we touch, and the air we breathe are part of the cancer equation. These changing and multiplying factors make it difficult to fight cancer–it’s a moving target in many ways. Overall, the US Centers for Disease Control (CDC) projects a 24% increase in new cancer cases among men from 2010 to 2020 and a 21% jump in women, for a total of about 2 million new diagnoses per year.
Moving from Theory to Clinical Practice
The work of fighting cancer isn’t just done in the lab–it’s also done in the library. Researchers understand that they don’t know everything and that what wasn’t written down by the best scientists is lost. So they engage in training and mentorship and look for clues in buried research that may have gone unnoticed. One example of a transformative cancer-fighting discovery being unearthed comes in the story of Propanc Biopharma (OTCBB: PPCB), an Australian company focusing on fighting cancer stem cells.
Propanc is turning a century-old theory into reality, building on the work of embryologist John Beard who proposed that pancreatic enzymes are our primary defense against cancer. That
The United States Patent and Trademark Organization recently approved composition of matter claims for Propanc’s core PRP technology, which aims to control cancer cell migration and inhibit tumor growth building on Prof. Beard’s work from 100 years ago. It’s strong protection for core intellectual property in a crucial market and legal environment for cancer and any other drugs. The company has 65 patents in force or pending, showing they’re building up both ammunition and armor for fighting cancer and remaining competitive as they move into human trials.
Big Pharma Spends Big Money
There are a variety of approaches to building and reinforcing a cancer treatment portfolio if you’re a large pharmaceutical company. There are those that gobble and those that nibble. Bristol Myers Squibb Co (NYSE: BMY) is buying Celgene Corp (NASDAQ: CELG) for a cool $74 billion, freaking out some investors who understand that nothing is certain. A deal like that is a deal, period.
Collaboration and cash that comes with milestones is the best way to keep up progress. The first roadblock to clear is regulatory approval, and then sales targets must be met. This can help investors breathe easy. AstraZeneca Plc (NYSE: AZN) took this approach in teaming up with Japan’s pharmaceutical powerhouse Daiichi Sankyo Company (OTCBB: DSKYF), which is working on what the company says is a treatment that beats the current standard of care in chemotherapy in patients with quickly spreading cancer. If the drug is as efficient as hoped and expected, AstraZeneca has a blockbuster on its hands, and you can bet there won’t be any behind-the-scenes monkey business to keep the treatment out of the public or doctors’ hands.
The Wealthy Venture Capitalist is a series of industry-focused investment articles focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in 4 of the markets hottest sectors.
Sign up for Alerts
Sign up for text message alerts: http://clk2.it/k7oF5z
Email newsletter sign up: http://wealthyventurecapitalist.com/newsletter/
Follow The Wealthy Venture Capitalist on Social Media
This report/release/profile is a commercial advertisement and is for general information and entertainment purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Venture Capitalist and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Venture Capitalist encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Venture Capitalist makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be ”forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as ”projects”, ”foresee”, ”expects”, ”will”, ”anticipates”, ”estimates”, ”believes”, ”understands”, or that by statements indicating certain actions ”may”, ”could”, or ”might” occur. Understand there is no guarantee past performance will be indicative of future results.
The Wealthy Venture Capitalist’s parent company has been, and will be, compensated an average of $6,500 per month over a 1-year contract by Propanc Health Group. We have also been compensated 8 million restricted common shares of Propanc Health Group by the Company, and will sell these shares into the market as soon as the 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.
Article written by Sam H.